
Assessing the Performance of 3D Pharmacophore Models in Virtual Screening: How Good are They?
Pharmacophore approaches have evolved to be one of the most successful tools in drug discovery, especially since the past two decades. 3D pharmacophore methods are now commonly used as part of more complex workflows in drug discovery campaigns, and have been successfully and extensively
applied in virtual screening (VS) approaches. This review provides a perspective of how to assess the performance of 3D pharmacophore models to be used in VS. Since 3D VS protocols are in general assessed by their ability to discriminate between active and inactive compounds, we summarize
the impact of the composition and preparation of modeling and external sets on the outcome of evaluations. Moreover, we highlight the significance of both classic enrichment parameters and advanced descriptors for the performance of 3D pharmacophore-based virtual screening methods.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics
Keywords: Drug design; Enrichment descriptors; InhA; Performance evaluation; Pharmacophore model; Virtual screening
Document Type: Research Article
Publication date: May 1, 2013
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites